Roche ’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A

Roche today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra ® (emicizumab) prophylaxis dosed once every four weeks in adults and adolescents (12 years of age or older) with haemophilia A with and without inhibitors to factor VIII.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news